GoodRx Partners with Novo Nordisk to Sell GLP-1s at $499/month

GoodRx will sell Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at $499/month. This move comes as telehealth platforms are increasingly seen as a way to provide greater access to in-demand products. GoodRx CEO Wendy Barnes stated that while the company could have offered a compounded alternative earlier, it chose to wait for FDA approval. The partnership aims to provide lawfully approved products, differing from Eli Lilly's strategy of selling vials on telehealth platforms.

GoodRx, the leading platform for medication savings in the U.S., has announced a significant partnership with Novo Nordisk to offer the company's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month. This move comes as telehealth platforms are increasingly recognized as a means to provide greater access to in-demand products.

GoodRx CEO Wendy Barnes stated that while the company could have offered a compounded alternative earlier, it chose to wait for FDA approval. This partnership aims to provide lawfully approved products, distinguishing it from Eli Lilly's strategy of selling vials on telehealth platforms.

The collaboration marks a significant milestone in improving access and affordability of these important, FDA-approved medications. According to Barnes, demand for GLP-1 medications is at an all-time high, with nearly 17 million people coming to GoodRx looking for savings and information on these drugs in the past year [2].

GoodRx's platform will connect consumers with over 70,000 retail pharmacies nationwide, making it easier for patients to access these critical treatments. The partnership also aims to fill the gaps in insurance coverage, helping to reduce friction in the healthcare system and accelerate speed to therapy.

This initiative aligns with Novo Nordisk's mission to improve access to effective, FDA-approved treatment. Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc., stated, "Our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform" [2].

The announcement comes as Novo Nordisk's weight-loss drug Wegovy is facing market share challenges from Eli Lilly's Zepbound. According to IQVIA, a healthcare analytics firm, weekly prescriptions for Zepbound increased by 199% year over year, compared to Wegovy's 40% increase [1].

References:
[1] https://finance.yahoo.com/news/goodrx-begins-selling-novo-nordisk-glp-1s-for-cash-price-130021684.html
[2] https://www.businesswire.com/news/home/20250818050537/en/GoodRx-Announces-Collaboration-with-Novo-Nordisk-to-Expand-Access-to-Ozempic-and-Wegovy-for-%24499-Per-Month